Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Interventions: DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Coronado, California • Montclair, California • Panorama City, California + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: PAH Therapies; Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: Post-Concussion Syndrome
Interventions: Craniosacral Therapy; Other
Lead sponsor: Special Therapies, Inc.; Other
Eligibility: 14 Years to 90 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Neoplasms, Advanced Solid Tumors
Interventions: JNJ-87890387; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Nashville, Tennessee

Conditions: Healthy Volunteer
Interventions: ABBV-903, Placebo for ABBV-903, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Diet, Healthy Growth
Interventions: Family support, BGCAA's after-school program with CATCH curriculum; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 5 Years to 11 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Biliary Tract Carcinoma
Interventions: Gemcitabine, Cisplatin, MEK162; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced or Metastatic Solid Tumors
Interventions: ERAS-007, ERAS-601; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more

Conditions: Healthy Subjects
Interventions: Norketotifen Oral Capsule (Cohort 1), Norketotifen Oral Capsule (Cohort 2), Norketotifen Oral Capsule (Cohort 3), Norketotifen Oral Capsule (Multiple Dose Cohort), Placebo Oral Capsule; Drug
Lead sponsor: Emergo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Normal Endometrial Physiology
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
Interventions: TAK-659, Nivolumab; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 9
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more

Conditions: Delayed Graft Function
Interventions: OPN-305, Placebo; Drug
Lead sponsor: Opsona Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more

Conditions: Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
Interventions: Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide; Behavioral · Drug
Lead sponsor: Noom Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Chronic Pain
Interventions: Cognitive Behavioral Therapy (CBT), Hypnotic Cognitive Therapy (HYP-CT), Mindfulness-Based Cognitive Therapy (MBCT); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Klippel-Feil Syndrome
Interventions: Ventilation, Intubation; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions: Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs; Dietary Supplement · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Tobacco Use Cessation
Interventions: Telephone Counseling for Tobacco Cessation, Usual Care; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Myeloma in Relapse
Interventions: Talquetamab, Daratumumab; Drug
Lead sponsor: Larysa Sanchez; Other
Eligibility: 70 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Myeloid, Acute, Hematologic Neoplasms
Interventions: Pimasertib; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Cancer
Interventions: SRK-181, anti-PD-(L)1 antibody therapy; Biological
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Fullerton, California • La Jolla, California • Los Angeles, California + 14 more

Conditions: Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions: Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care; Device · Procedure
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 6
States / cities: Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

Craniosacral Therapy for Concussion Symptoms

A Study of JNJ-87890387 for Advanced Solid Tumors

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

'Food, Fun, Fresh, Family' Program for Healthy Eating and Growth for Elementary-age Children.

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

Endometrial Basis for Infertility in Women With Recurrent Implantation Failure and Pregnancy Loss

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

Matching Adults to Treatments for Chronic Pain (MATCH) Study

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Airway Management of Pediatric Patients With Klippel-Feil Syndrome

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

Telephone Counseling for Tobacco Cessation

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Trial of Pimasertib in Hematological Malignancies

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds